Navigation Links
Axel Ullrich named winner of 2009 Dr. Paul Janssen Award for Biomedical Research
Date:7/1/2009

London, 1 July, 2009 Johnson & Johnson today announced that Axel Ullrich, Ph.D., director of the Department of Molecular Biology at the Max Planck Institute of Biochemistry in Germany, whose discoveries have led to novel cancer therapies including Herceptin (trastuzumab) , is the winner of the 2009 Dr. Paul Janssen Award for Biomedical Research. An independent committee of world-renowned scientists selected Dr. Ullrich, who on September 8 will receive a $100,000 prize during a ceremony in Beerse, Belgium.

"Dr. Ullrich was chosen for his pioneering work in applying molecular biology and molecular cloning to the discovery of protein therapeutics for the treatment of a wide range of diseases, including diabetes and cancer," said Solomon Snyder, M.D., distinguished service professor of Neuroscience, Pharmacology and Psychiatry, Johns Hopkins School of Medicine and chairman of The Dr. Paul Janssen Award Selection Committee.

"He is one of few basic scientists whose work not only has influenced academic research, but also has helped millions of patients suffering from major chronic diseases," Snyder continued. "We received a number of outstanding nominations for this year's Award and are pleased to acknowledge Dr. Ullrich with this distinction. His work has had a remarkable impact on human health and truly embodies the efforts of the Award's namesake, 'Dr. Paul,' who helped save millions of lives through his contribution to the discovery and development of more than 80 medicines."

Ullrich has pioneered the translation of genomics-based discoveries into novel approaches for the treatment of major diseases. Working at Genentech, Inc. in the early 1980s, he developed genetically engineered human insulin, the first therapeutic derived from gene cloning. In 1987, Ullrich and collaborators discovered that the neu/HER2 gene is amplified and overexpressed in more than 30 percent of invasive breast cancers. HER2 was chosen for the development of an entirely novel cancer therapy, culminating in the production of an anti-HER2 monoclonal antibody that since 1998 has been used successfully to treat patients with metastatic breast cancer. This was the first targeted therapeutic agent developed on the basis of a newly discovered gene with an oncogenic function in human cancer.

In the early 1990s, Ullrich identified the signaling system involved in regulating tumor angiogenesis, the growth of blood vessels in tumors. He discovered that inhibiting a key player in the signaling system (called vascular endothelial growth factor receptor or VEGFR) suppresses the generation of blood vessels in tumors and slows down cancer cell growth. Years later, a small molecule inhibitor of the VEGFR2 kinase function was developed, from which a derivative was approved in 2006 for the treatment of kidney carcinoma and gastro-intestinal stromal tumors.

"It is an honor to receive an award of this stature and to be recognized among so many outstanding scientists," said Ullrich. "Dr. Paul is a legend whose work had a tremendous impact on combating some of the world's most serious diseases. Four of the more than 80 medicines he developed are on the World Health Organization's list of essential medicines."

"Johnson & Johnson is pleased the Selection Committee chose Dr. Ullrich as the recipient of the 2009 Dr. Paul Janssen Award, as we believe that his discoveries capture the spirit and legacy of Dr. Paul," said Paul Stoffels, M.D., global head, Research & Development, Pharmaceuticals, Johnson & Johnson. "Dr. Paul's passion for his work and dedication to creating life-saving therapies for the individuals most in need should continue to serve as an inspiration to the scientific community as we carry on with our quest to care for the world, one patient at a time."


'/>"/>

Contact: Seema Kumar Johnson & Johnson Pharmaceutical Services, L.L.C
skumar10@its.jnj.com
908-218-6460
Porter Novelli
Source:Eurekalert

Related biology news :

1. American Journal of Botany named a top 10 most influential journal of the century
2. New species of phallus-shaped mushroom named after California Academy of Sciences scientist
3. 3 prominent Cell Press journals named among the 100 most influential journals in past 100 years
4. Three prominent Cell Press journals named among the 100 most influential journals in past 100 years
5. Two Hutchinson Center researchers named HHMI Early Career Scientists
6. Peter Baumann named Howard Hughes Medical Institute Early Career Scientist
7. Whitehead member Peter Reddien named HHMI Early Career Scientist
8. Wildlife biologist named Roger Tory Peterson Medal recipient, speaker
9. Lockheed Martin Named Biometrics Company of the Year by Frost and Sullivan
10. Lockheed Martin Named Biometrics Company of the Year by Frost and Sullivan
11. UC San Diego senior named Churchill Scholar for extraordinary undergraduate research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/10/2016)... 10, 2016 --> ... report "Identity and Access Management Market by Component (Provisioning, ... Governance), by Organization Size, by Deployment, by Vertical, and ... MarketsandMarkets, The market is estimated to grow from USD ... 2020, at a Compound Annual Growth Rate (CAGR) of ...
(Date:3/9/2016)... -- This BCC Research report provides an overview of ... (RNA Seq) market for the years 2015, 2016 and ... data analysis, and services. Use this report ... such as RNA-Sequencing tools and reagents, RNA-Sequencing data analysis, ... segment and forecast their market growth, future trends and ...
(Date:3/9/2016)... March 9, 2016  Crossmatch ® , a ... solutions, today announced the addition of smart features ... multi-factor authentication platform. New contextual and application-specific ... step-up security where it,s needed most — while ... DC . --> Washington, ...
Breaking Biology News(10 mins):
(Date:4/28/2016)... NEW YORK , April 28, 2016 /PRNewswire/ ... biotechnology acceleration company reports the Company,s CEO  was ... capital titled Accelerators Enter When VCs Fear To ... Life Science Leader magazine is an ... work for everything from emerging biotechs to Big ...
(Date:4/27/2016)... ... ... Cambridge Semantics, the leading provider of Smart Data analytic and ... named to The Silicon Review’s “20 Fastest Growing Big Data Companies of 2016.” ... needs of end users facing some of the most complex data challenges in the ...
(Date:4/27/2016)... RESEARCH TRIANGLE PARK, N.C. , April 27, ... ) announced today that Martine Rothblatt , Ph.D., ... provide an overview and update on the company,s business ... Care Conference. The presentation will take place ... Time, and can be accessed via a live webcast ...
(Date:4/27/2016)... (PRWEB) , ... April 27, 2016 , ... Global ... the GSCG Advisory Board. Ross is the founder of GSCG affiliate Kimera Labs in ... Miami, where he studied hematopoietic stem cell transplantation for hematologic disorders and the suppression ...
Breaking Biology Technology: